Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17967514 | 0.95 | ENPP1 (0.59) | ENPP1PDE10AEGFRCSF1RKDR | |
| SCHEMBL16295087 | 0.90 | ENPP1 (0.44) | ENPP1ELANEEGFRKDRALDH1A1 | |
| SCHEMBL16294230 | 0.89 | ENPP1 (0.54) | ENPP1EGFRKDRFLT1 | |
| SCHEMBL19874812 | 0.88 | ENPP1 (0.41) | ENPP1KDRALDH1A1 | |
| SCHEMBL18013041 | 0.84 | PDE10A (0.38) | PDE10AELANEEGFRKDRALDH1A1 | |
| SCHEMBL1999978 | 0.83 | ENPP1 (0.54) | ENPP1PDE10AEGFRKDRALDH1A1 | |
| SCHEMBL17967513 | 0.83 | ENPP1 (0.41) | ENPP1ELANEEGFRKDR | |
| SCHEMBL16294778 | 0.79 | ATM (0.43) | ENPP1EGFRKDRFLT1 | |
| SCHEMBL18013038 | 0.79 | PDE10A (0.46) | ENPP1PDE10AEGFRCSF1RKDR | |
| SCHEMBL3427630 | 0.78 | ENPP1 (0.63) | ENPP1PDE10AEGFRCSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058340-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | ERASCA, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230115366-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| WO-2014200872-A9 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014200872-A9 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014200872-A1 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014200872-A1 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | ENPP1 1422/4885PDE10A 4423/4885ELANE 1126/4885 |
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | ENPP1 1876/4885PDE10A 3326/4885ELANE 3136/4885 |
| US-20230115366-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | ENPP1 2189/4885PDE10A 3308/4885ELANE 3113/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | ENPP1 2000/4885PDE10A 3482/4885ELANE 3063/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | ENPP1 2189/4885PDE10A 3308/4885ELANE 3113/4885 |
| US-20240058340-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | ENPP1 2000/4885PDE10A 3482/4885ELANE 3063/4885 |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | ENPP1 3752/4885PDE10A 4072/4885ELANE 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.